Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 361-380 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 361 | Romanian InSpace Engineering lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources only provides older membership context that Romanian InSpace Engineering was part of the consortium that developed the EMISAR satellite via article; that is insufficient for a current positive thesis within this ranking window. Why now: No why-now catalyst is evidenced because there are no retained 90-day evidence. Caveats: Reviewed evidence references but provides no. Single historical membership-support mention only. No retained evidence after recent evidence window. |
| 362 | Safran lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources does not provide direct positive company-specific evidence within the available 90-day evidence set. Only older or contextual references are cited in the membership rationale, including thematic propulsion or battery market reports and a reference to expanded small-satellite propulsion manufacturing, but no direct post-recent evidence window evidence is available for scoring. Why now: There is no current catalyst in the reviewed sources. Coverage debug shows 270 article IDs considered but 0 article IDs after recent evidence window and 0 evidence available after dedupe, so recency-based thesis formation is not supported. Caveats: Membership rationale references article IDs 2026-04, and, but no are provided in the reviewed sources, so they cannot be cited as factual scoring evidence under the the evidence standard. Evidence recent evidence review shows 0 kept rows after the 90-day cutoff. |
| 363 | SatLeo Labs lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence rationale says SatLeo Labs raised seed funding for a multispectral and thermal Earth observation constellation, but no retained article/evidence are available here to support a stronger opportunity ranking. Why now: No retained within the recent evidence window evidence are provided, so there is no reviewed sources-supported why-now beyond cohort inclusion rationale. Caveats: Only membership rationale is available; no citeable retained evidence. Small-company universe but zero available evidence after recent evidence window. |
| 364 | SciTec lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources say AI software came from a SciTec subsidiary in connection with Firefly's lunar imaging service, but this is only supporting article context without retained direct evidence, so it does not support a strong long-horizon opportunity thesis for SciTec itself. Why now: No current catalyst is established because the reviewed sources retains no company-specific evidence after the 90-day filter. Caveats: Phase-2 rationale references, but no or retained summary is available in the reviewed sources. Support level is provisional single-article context. No direct company-specific positive or negative evidence remain after recent evidence window. |
| 365 | SEALSQ Corp lowweak | Opp 1 Risk 2 | Thesis: Reviewed evidence membership rationale says SEALSQ is directly involved with WISeSat in a planned 100-satellite QSOC constellation and post-quantum satellite launches, which could indicate long-horizon strategic relevance, but no usable direct positive evidence or article survive the 90-day served evidence set in these reviewed sources. Why now: Why now is weak because the 90-day reviewed sources contain no available evidence after recent evidence window for SEALSQ, despite article history existing in the broader corpus. Caveats: No direct positive or negative evidence available after recent evidence window. Membership rationale references article IDs and, but the reviewed sources provide no for them, so they cannot be cited as factual support under the the evidence standard. |
| 366 | SEALSQ Corp lowweak | Opp 1 Risk 1 | Thesis: Reviewed evidence context links SEALSQ to post-quantum payload development with WISeSat, but there is no retained direct positive evidence inside the 90-day recent evidence window to support a 1 year+ opportunity thesis. Why now: There is no usable current evidence because articles after recent evidence window = 0 and evidence after recent evidence window = 0 following the March 29, 2026 cutoff. Caveats: No surviving recent evidence window-qualified evidence. Space relevance in reviewed sources rationale does not establish direction. |
| 367 | SES S.A. lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources membership rationale places SES in satellite communications and infrastructure contexts, but there are no available within the recent evidence window evidence or article details to support a directional opportunity thesis for this screen. Why now: Why-now is weak because no reviewed evidence are available after recent evidence window, so recency and catalysts cannot be assessed from the reviewed sources. Caveats: Membership rationale references and, but no corresponding available article summaries or evidence are provided. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Cohort membership does not establish opportunity. |
| 368 | Sidus Space Inc. lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources' membership rationale references payload and agreement expansion activity, but no retained within the recent evidence window direct evidence or article summaries are available here to support a positive investment-style thesis. Why now: There is no retained dated company evidence after the 90-day recent evidence window; timing support for a 1 year+ thesis is absent in the reviewed sources. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. The membership rationale mentions article IDs, and, but no or retained evidence content are provided in these reviewed sources. |
| 369 | SkyFi lowweak | Opp 1 Risk 1 | Thesis: No direct positive evidence is available, so there is no supportable upside thesis from these reviewed sources alone. Why now: Membership rationale says SkyFi was mentioned as a commercial access partner for Vantor's satellite imagery constellation in article, but this is only contextual and no or direct evidence are provided. Caveats: Partner context is weaker than direct company evidence. No evidence available after recent evidence filtering. Referenced has no in the reviewed sources. |
| 370 | Skyfora lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources only says Skyfora appears in a funding roundup with a €6.5M raise, but no retained direct evidence or article summaries are provided after the 90-day recent evidence window, so there is not enough evidence to support a positive 1 year+ thesis. Why now: No within the recent evidence window company-specific catalyst is provided. The reviewed sources reports zero reviewed evidence after the 90-day cutoff for Skyfora, so recency is insufficiently grounded. Caveats: Phase-2 rationale references a €6.5M raise tied to: but no representative article, or retained evidence row is provided in these reviewed sources, so it cannot be used as direct scored evidence. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership review status is not directional proof. |
| 371 | Solestial Inc. lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable from these reviewed sources because no retained direct positive evidence is provided inside the recent evidence window. Why now: No current catalyst can be established from the reviewed sources; the company has zero evidence after recent evidence window. Caveats: Phase-2 rationale says York Space Systems acquired Solestial and cites: but no article summary or is provided here, so it cannot be used as cited factual support. Coverage debug shows 4 articles considered and 0 article IDs after recent evidence window. Absence of evidence is not positive or negative proof. |
| 372 | Solstar Space Company lowweak | Opp 1 Risk 1 | Thesis: The membership rationale says Solstar's Deke Space Communicator operated in orbit and achieved TRL 9 with two-way data transmission and onboard Wi-Fi, which could imply commercialization potential, but no direct positive evidence or article summaries are available for scoring in these reviewed sources. Why now: The reviewed sources contain no reviewed evidence after recent evidence window for this company, preventing a recency-based 1 year+ ranking judgment beyond watchlist status. Caveats: Membership rationale references article, but no direct summary or evidence row is available here for citation. Coverage debug shows zero available evidence after recent evidence window. Private-company status is not itself positive or negative. |
| 373 | Space Systems/Loral, LLC (SSL) lowweak | Opp 1 Risk 1 | Thesis: SSL is referenced in membership rationale as appearing among key players in an optical satellite market report, but that is only article-level industry context and no direct within the recent evidence window evidence is available. Why now: No current catalyst can be established because coverage debug shows 0 article IDs after recent evidence window and 0 evidence after recent evidence window. The rationale cites: without a in these reviewed sources. Caveats: Only industry-report context is referenced in membership rationale. No direct event/fact evidence survived the recent evidence window. |
| 374 | Space42 lowweak | Opp 1 Risk 1 | Thesis: Space42 is described in membership rationale as operating a SAR Earth observation constellation with satellites entering full operation, but the reviewed sources retains no direct evidence or article summaries within the recent evidence window to support a current opportunity ranking. Why now: Why now is weak because coverage data shows no articles after recent evidence window and no evidence after recent evidence window. Caveats: Membership rationale references article IDs but no are provided, so they cannot be used as cited factual support here. Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. |
| 375 | SpaceLocker lowweak | Opp 1 Risk 1 | Thesis: There is not enough retained evidence in the recent evidence window to underwrite a durable opportunity case, despite membership rationale describing a first shared satellite mission. Why now: No article-level or event-level evidence were retained after the March 29, 2026 recent evidence window cutoff; recency for the membership rationale is therefore unusable for ranking. Caveats: Membership rationale references article, but no representative article summary or retained evidence row is included. Single-article universe with zero retained rows limits confidence materially. |
| 376 | SpaceLogistics (Northrop Grumman) lowweak | Opp 1 Risk 2 | Thesis: The reviewed sources contain a descriptive article saying SpaceLogistics provides cooperative in-orbit satellite servicing using commercial servicing vehicles, which supports strategic relevance as a business category, but the only cited article is dated March 4, 2025 and was dropped by the 90-day recent evidence window. Why now: Why now is weak because the only cited article, March 4, 2025), falls outside the 90-day recent evidence window and was dropped; recency therefore does not support an active thesis here. Caveats: No evidence were kept after recent evidence filtering. Cannot rely on dropped 2025 evidence for a current ranking. Company-category relevance is not sufficient for a directional opportunity thesis. |
| 377 | Spaceworks lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources only says Momentus's fully booked Vigoride 8 mission will carry a Spaceworks COSMIC payload, which indicates some space-payload involvement but does not establish a durable company-specific opportunity thesis for Spaceworks. Why now: No within the recent evidence window retained catalyst is available. The phase-2 rationale references, but no, timestamp, or retained summary is included. Caveats: Support is provisional single-article context only. No retained direct evidence after recent evidence window. Payload mention does not prove company-level commercial traction. |
| 378 | Spacium lowweak | Opp 1 Risk 2 | Thesis: Spacium has a potentially attractive refueling/logistics angle, and an older article says it raised an oversubscribed $6.3 million seed round, but that dated evidence is outside the 90-day recent evidence window and therefore cannot support a current-ranked opportunity thesis. Why now: The only cited article is dated January 23, 2025, and the reviewed sources explicitly shows it was dropped by the 90-day recent evidence window cutoff of March 29, 2026. Caveats: All dated evidence was excluded by recent evidence window. Do not use out-of-window article as current recency proof. |
| 379 | SSC Space lowweak | Opp 1 Risk 1 | Thesis: No positive thesis is supportable from these reviewed sources because no direct positive evidence remains after recent evidence filtering. Why now: There is no retained within the recent evidence window evidence for a current catalyst. Caveats: Phase-2 rationale mentions a sponsored article and a partnership supporting Firefly's Blue Ghost lunar lander antennas, citing, but no or article summary is provided in these reviewed sources. Coverage debug shows 3 articles considered and 0 after recent evidence window. Sponsored-article context would be weaker than direct event/fact evidence even if fully provided. |
| 380 | ST Engineering lowweak | Opp 1 Risk 1 | Thesis: Only weak, supporting article context suggests ST Engineering had involvement in SAR and AI geospatial analytics for satellite ocean surveillance, but the reviewed sources contain no direct positive evidence after the 90-day recent evidence window and no article to substantiate a durable 1 year+ opportunity thesis (: not provided in reviewed sources). Why now: There is no usable dated direct evidence inside the recent evidence window; the reviewed sources explicitly shows articles after recent evidence window = 0 and evidence after recent evidence window = 0, so recency-based timing is unsupported. Caveats: No direct evidence remained after the recent evidence filter. Representative articles are empty, so no is available in the reviewed sources. Membership rationale is weaker than company-specific event evidence. |
Risk view
Showing rows 61-80 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 61 | Xoople mediummedium | Opp 6 Risk 4 | Thesis: Article-level context also highlights structural Earth observation monetization difficulty and long procurement cycles, creating real commercialization risk even after the raise. Why now: Xoople closed a $130 million Series B on April 6, 2026/07 and articles say the capital is for building out its constellation; for a 1 year+ horizon, that financing can enable product and deployment progress, but the same dated coverage warns the market has historically been hard to monetize. Evidence
Caveats: Positive support is mostly supporting article context rather than positive evidence. Commercialization warning is article context, not a company-specific deterioration event. No direct customer, backlog, or launch milestone evidence is available. |
| 62 | AAC Clyde Space AB lowweak | Opp 3 Risk 3 | Thesis: There is no direct adverse evidence in the reviewed sources, so risk is moderate-low and mostly reflects inability to verify current contract progression, funding conversion, or execution status from available evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources' recent evidence review and coverage data show zero available evidence after recent evidence window despite the membership rationale referencing a material contract. Caveats: No current evidence is provided for Contract claim appears only in membership rationale, not in available direct evidence fields. No recency-confirmed follow-through evidence is available. |
| 63 | Aavuus mediummedium | Opp 5 Risk 3 | Thesis: Aavuus remains early-stage, and the evidence is supporting article context rather than direct positive events; the same article describes only pre-seed funding, which implies execution and scaling risk over a 1 year+ horizon. Why now: The opportunity is timely because the retained article is dated June 9, 2026 and describes a current financing and product build phase rather than stale background context. That said, recency comes from source date/article date, and evidence grounding is still article-level rather than direct fact/events., June 9, 2026 Evidence
Caveats: Evidence is weak context and supporting article context, not direct structured positive event evidence. No explicit customer, contract, revenue, or regulatory milestone is cited. Same article appears in multiple rows and is not independent confirmation. |
| 64 | Applied Atomics lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the reviewed sources' membership rationale describes it as a startup that emerged from stealth and raised only a $4M pre-seed, implying early-stage execution and financing risk, but this is not backed by available dated evidence in the ranking payload. Why now: There is no available dated evidence in the reviewed sources after recent evidence filtering, so recency-based ranking support is weak. Caveats: No representative articles or evidence are available after recent evidence filtering for ranking support. The phase2 membership rationale mentions a $4M pre-seed and Star Reacher Network, but the cited supporting articles are not provided with usable article summaries or evidence in these reviewed sources. |
| 65 | Astrolab lowweak | Opp 3 Risk 3 | Thesis: No direct negative evidence is available; the main risk in this ranking is evidence insufficiency rather than a documented adverse development. Why now: Why-now support is weak because coverage data shows no evidence after recent evidence window, so the cited lunar contract context cannot be refreshed from available evidence. Caveats: Phase2 rationale cites, and: but no representative article or evidence are available for direct citation. Coverage data reports articles after recent evidence window = 0 and evidence after recent evidence window = 0. Private-company watch item rather than high-conviction ranked candidate. |
| 66 | Astroscale lowweak | Opp 5 Risk 3 | Thesis: No direct negative evidence is available. Remaining risk comes from the lack of post-recent evidence window evidence proving contract conversion, revenue realization, or mission execution scale. Why now: Why now is relatively constructive because a named partnership for on-orbit services can matter over a long strategic horizon, but exact timing and materiality cannot be validated from the reviewed sources because only membership rationale is visible. Caveats: Membership rationale references article ID: but the reviewed sources provide no or article summary. Relation counts are present in support metadata, but relations are context-only unless separately policy-gated. No direct positive or negative evidence arrays are populated. |
| 67 | Axelspace Corporation lowweak | Opp 3 Risk 3 | Thesis: No material negative evidence is present; risk is mainly execution and evidence-gap risk because current launch timing, deployment success, and monetization are not substantiated by the available reviewed sources evidence (: unavailable in reviewed sources). Why now: Why now is weak because the reviewed sources references a potentially important constellation expansion but provides no post-recent evidence window available evidence to confirm status or timing. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Recency of constellation expansion cannot be validated from reviewed sources fields. |
| 68 | CAS Space lowweak | Opp 2 Risk 3 | Thesis: Risk is modestly elevated because the membership rationale describes IPO and reusable rocket development ambitions, both of which imply capital intensity and execution risk, but there is no available adverse evidence. Why now: There is no usable dated evidence available after recent evidence filtering, so the reviewed sources does not provide a clear timing catalyst. Caveats: The membership rationale references an IPO and Lijian-1 launch activity, but those source articles are not included with ranking-usable details in these reviewed sources. |
| 69 | CesiumAstro lowweak | Opp 5 Risk 3 | Thesis: The positive financing evidence is stale relative to the reviewed sources' 90-day recent evidence window. The article is dated February 14, 2026, which the reviewed sources say was dropped by the recent evidence filter, so there is no current-window evidence confirming whether financing momentum, backlog conversion, or product adoption continued Why now: There is no fresh catalyst inside the 90-day evidence window. The visible article was published on February 14, 2026 and is outside the cutoff date of March 29, 2026, so it is useful as background but weak for recency-sensitive ranking Evidence
Caveats: The visible positive article is outside the 90-day recent evidence window cutoff and was dropped from reviewed evidence. External supporting source context is allowed as evidence context but is not merged into primary data source. |
| 70 | ClearSpace mediummedium | Opp 7 Risk 3 | Thesis: Risks center on execution and evidence quality rather than explicit adverse news. The financing article carries internal chronology ambiguity because the page was published in 2026 but references a January 19, 2023 financing round, and the overall reviewed sources lack direct negative events, contract-performance data, or milestone completion proof. Why now: Why now is supported by recent dated context: on June 24, 2026, SpaceNews reported ClearSpace signed an MOU with Shield Space to develop sovereign space defense capabilities for the UK and allies, indicating adjacent market expansion. On May 19, 2026, the company site said it had finalized a EUR 26.7 million Series A and was ramping operations ahead of ClearSpace-1 scheduled to launch in 2026. These dated items fit a 1 year+ horizon because they point to ongoing commercialization and mission preparation. Evidence
Caveats: Most evidence is supporting article context, not direct positive events. The financing article published on May 19, 2026 references January 19, 2023 for the Series A round, so funding recency versus page recency should not be conflated. |
| 71 | D-Orbit lowweak | Opp 4 Risk 3 | Thesis: No direct negative evidence is present. Risk remains moderate because the evidence base is only one cited article with no available direct events, leaving uncertainty on commercialization, timeline, and conversion from demonstration activity to durable revenue. Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision. Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction. |
| 72 | Dawn Aerospace mediummedium | Opp 7 Risk 3 | Thesis: Risk is non-trivial because the thesis depends on execution of a global rollout in a capital-intensive reusable space transportation market, but the reviewed sources does not show direct adverse events. Risk is therefore moderate rather than high. Why now: The key catalyst is recent and explicit: on June 16, 2026 the company announced the Series B close and said the proceeds will finance global rollout and scaling of commercial and operational teams in the US and Europe. Evidence
Caveats: Evidence comes from a company-published article, so it is not fully independent. No direct structured positive event row is provided beyond supporting article context. |
| 73 | Earth Eye Co lowweak | Opp 2 Risk 3 | Thesis: Because the reviewed sources frames the company around surveillance/spy satellite activity rather than commercial traction, and provides no direct positive operating evidence, the name screens as a limited-visibility watchlist with modest evidence-based risk. Why now: Why now is weak because there are no available post-recent evidence window evidence, no article summaries, and no clear near- or long-horizon catalyst beyond generic association with a surveillance satellite. Caveats: Membership rationale cites article IDs and, but the reviewed sources provide no. Company is private and evidence coverage inside the recent evidence window is empty. |
| 74 | EDGX lowweak | Opp 4 Risk 3 | Thesis: Execution and financing risk remain material because the reviewed sources contain no kept direct evidence on follow-on funding, customer adoption, revenue conversion, or post-demo performance; technology demonstration does not by itself prove scale-up. Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence. Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk. |
| 75 | Ellipsis Drive lowweak | Opp 4 Risk 3 | Thesis: Risk is mostly commercialization uncertainty. The reviewed sources does not provide direct negative evidence, but it also lacks direct available proof of revenue, customer conversion, or broader market adoption. Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided. Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue. |
| 76 | EON Space Labs lowweak | Opp 1 Risk 3 | Thesis: The reviewed sources' clearest adverse context is that EON Space Labs was identified as one of the Indian private space companies affected by a PSLV failure, which could create execution, schedule, or financing ripple effects over a 1 year+ horizon, though the underlying article detail is not surfaced in the scoring evidence fields. Why now: Why now is stronger than for most names here because the phase2 rationale specifically ties EON Space Labs to a PSLV failure context via article: implying a concrete event rather than generic company context. However, conviction remains low because the reviewed sources omits the underlying event summary and dates in the evidence exposed here. Caveats: The adverse signal appears only in phase2 rationale, not in direct negative evidence. No article summary, quote, or timing detail is provided in the scoring fields. Impact magnitude on EON specifically cannot be quantified from these reviewed sources alone. |
| 77 | Eycore mediumweak | Opp 5 Risk 3 | Thesis: Risk remains moderate because the reviewed sources offers only one supporting article context and no direct positive event row beyond that summary, leaving unclear whether the satellite is generating revenue, delivering performance, or leading to follow-on orders. Why now: Why now is the dated first-satellite launch article from May 5, 2026, which is recent within the 90-day recent evidence window and relevant to a long-horizon de-risking story, though still early-stage. Evidence
Caveats: Evidence is supporting article context only, not a stronger structured positive event row. Single-article universe limits corroboration. No financing, customer, revenue, or performance follow-through evidence is provided. |
| 78 | GITAI mediummedium | Opp 6 Risk 3 | Thesis: Execution and commercialization risk remain meaningful because the retained evidence is still mainly company-provided article context and a technology demonstration milestone, not third-party validated contract wins, revenue conversion, or mission success; an undated directory listing that GITAI is 'operating' is weaker context and not recency proof. Why now: The key catalyst is recent and inside recent evidence window: on June 16, 2026, GITAI announced completion of the S3 flight model for an on-orbit servicing demonstration mission, which is directly relevant to a 1 year+ horizon because it may precede launch, demonstration, and downstream defense/commercial adoption over the next year. Evidence
Caveats: Primary evidence is from the company itself. No retained independent customer, contract, or revenue evidence is provided. The spaceindex.io entry is undated and should not be treated as recency proof. |
| 79 | Goonhilly Earth Station Ltd lowweak | Opp 3 Risk 3 | Thesis: The same reviewed sources rationale says Goonhilly is being acquired by Intuitive Machines, which can create integration, ownership, and business-state uncertainty over a 1 year+ horizon. Because no retained dated evidence are available, this risk is only moderately ranked. Why now: The only 'why now' available is the reviewed sources' statement that Goonhilly is being acquired by Intuitive Machines, cited in phase-2 support, and: but no, timestamps, or retained evidence are provided, so recency and sequence cannot be validated. Caveats: The reviewed sources rationale states Goonhilly has ground-station/COMSAT revenue and is being acquired by Intuitive Machines, tied to, and: but no or retained evidence are present. Coverage debug still shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Because chronology cannot be verified, transaction-state claims should be treated cautiously. |
| 80 | ICEYE highstrong | Opp 9 Risk 3 | Thesis: The reviewed sources does not show material adverse company-specific events; main risk is that most support is financing/context evidence rather than audited operating metrics or margins. Why now: On June 9, 2026 ICEYE disclosed a €450 million primary Series F at valuation above €10 billion, with total round size above €1 billion including secondary, and later June context also referenced a €300 million revolving credit facility and additional sovereign satellite demand; those are recent business-state signals for a 1 year+ horizon. Evidence
Caveats: Some support is supporting article context rather than company-specific positive evidence. Several supporting demand/customer references are undated, so recency is uncertain for those claims. |